@PoolbegPharma research document
Please let me know if you find this useful - feedback is helpful.
This is a statement of facts - not Investment advice
#POLB#AIM#Investment@HLInvest
@PoolbegPharma has the potential to transform cancer treatment. By moving #POLB administration of cancer immunotherapies away from centralised specialist cancer centres in large cities, into community hospitals & potentially into the patients GP practice
https://t.co/jq6lzVQQ4A
During our panel discussion at the @_investorsummit our CEO Jeremy Skillington discussed the benefits of Orphan Drug Designation (ODD) and how this award from the FDA significantly benefits POLB 001’s development.
👉7-year U.S. market exclusivity
💪Tax benefits for clinical trials
✅Potential waiver exemption of Prescription Drug User Fee Act application fees
📞Direct line to FDA around clinical trials
Learn more about our ODD announcement for POLB 001 here:
https://t.co/x4TT1KlNJw
#POLB #ODD #FDA #ScientificResearch #MarketExclusivity #ClinicalTrials #CRS #Immunotherapy #Cancer #Oncology
Tune into our snippet from CEO Jeremy Skillington, who provides a timeline for POLB 001’s milestones
✅Trial to commence before the end 2025
☑️Interim data in H1 2026
🚀Trial completion by H2 2026
🤝Take datasets, intellectual property to partnering with Big Pharma
➡️ODD accelerates progression into the clinic
👉Potential to go to a straight into a Phase 3
Learn more about POLB 001, a Preventative Therapy Targeting Cancer Immunotherapy-Induced CRS:
https://t.co/xDBLqtZIB4
#POLB #InvestorSummit #CRS #Immunotherapy #Treatments #ScientificResearch #Oncology #CytokineReleaseSyndrome #Inflammation
Poolbeg Pharma is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs.
We are led by a team dedicated to improving global health and with a track record of success in the pharmaceutical industry.
Our high value programmes target areas of high unmet medical need including cancer immunotherapy-induced Cytokine release Syndrome (CRS) and metabolic conditions such as obesity with our oral encapsulated GLP-1 programme.
In May 2025, we had an oversubscribed fundraise, which resulted in us having a strong cash runway into 2027, funding our near-term clinical value inflection points in oncology and obesity.
We are partnering focused, with programmes that are attractive for Pharma partnering.
Learn more:
https://t.co/4eqcMhz6hs
#POLB #Investors #ReasonstoInvest #AIM #Market #Pharma
It could be argued that the share price of #POLB went the wrong way in a big way following the announcement of what should have been regarded as a stellar deal with HOOKIPA. It seems that the market is starting to warm to the proposed combo. @ZaksTradersCafe
I see #POLB heading to 5p this afternoon with this morning vote of confidence by Gilead @GileadSciences
$Hookipa will move on US open
Pushing @PoolbegPharma higher
Bid creeping 📈
Good luck all 😎
I see #POLB heading to 5p this afternoon with this morning vote of confidence by Gilead @GileadSciences
$Hookipa will move on US open
Pushing @PoolbegPharma higher
Bid creeping 📈
Good luck all 😎
Remember when everyone was complaining about #TM1 ?
Similar to #RBD
It’s coming 📈
@ReaboldPLC
Cash in the bank 💰
Multiple long term projects 👷🏼♂️
Low low MCap 📉
New due 🗞️
All I hear is greedy directors
Greedy directors that bought @ 0.07
They won’t be losing out
Some clarity on the liquidation of #Made
First interim payment to be made by month end
1.36p per share
Fingers crossed for a tidy final payment
@madedotcom
@iamTomOrange @power_thompson It's a classic nobody wants em til everybody does and at sub £5 mill mcap with £7+mill cash any news sends it on it'd way
In the meantime buy cheap cheap and stay in the long grass #RBD